KR20190084732A - A composition for improving, preventing and treating obesity comprising fermented pollack skin - Google Patents

Abstract

The present invention relates to a composition for alleviating, preventing, and treating obesity containing a Pollack skin fermentation product as an active component. Since a fermented dry extract of the present invention has an excellent obesity inhibition effect, it is possible to have an effect on alleviating obesity as well as liver diseases, and also have an effect on a wide range of diseases, such as metabolic syndrome and the like.

Description

TECHNICAL FIELD [0001] The present invention relates to a composition for improving, preventing and treating obesity,

The present invention relates to a composition for improving, preventing and treating obesity, which comprises a fermented shell peel.

Obesity is a phenomenon caused by an imbalance in consumption and consumption of energy, which means that the body is over-accumulated. Although it is not clear yet why the cause is caused by various causes, it is generally recognized that it is caused by excessive calorie intake, endocrine disruption, lack of exercise, genetic factors, and the like. It is also commonly referred to as lifestyle-related diseases because it is closely related to lifestyle habits. The worldwide obesity population is steadily increasing. As the income level and eating habits are westernized, the number of obese people in Korea is increasing rapidly. According to the national health statistics, the prevalence of obesity over 19 years of age continuously increased from 26.0% in 1998 to 31.0% in 2008, which is 32.2% in the United States (over 20 years old, body mass index 30kg / Similar level. Obesity has become a serious social problem, and various measures and active researches are under way in Korea to prevent obesity, which is a major cause of adult diseases. As a method for healing obesity, there are improvement of lifestyle such as eating, drug administration, and surgery. Recently, as the market for health functional foods has increased, many attempts have been made to improve functional foods in parallel with dietary control. Has been enacted, and a variety of health functional materials and foods have been licensed by the Korea Food and Drug Administration. Although many efforts have been made to prevent, ameliorate, or treat obesity, obesity is still increasing.

On the other hand, as the living standards and income of modern people have increased and interest in health has increased, the development of natural products and herbal medicine functional foods has been actively promoted all over the world, and the development of medicines targeting specific efficacies such as antimicrobial agents and anti- There is a growing tendency to separate, purify and formulate pharmaceutical active ingredients from natural herbal medicines.

Accordingly, there is still a need for a composition for preventing, alleviating, or treating an antimicrobial composition derived from natural products or herbal medicines and obesity.

[Prior Patent Literature]

Korean Patent Publication No. 10-2014-0072418

The present invention has been made in view of the above needs, and it is an object of the present invention to provide a novel composition for preventing and treating obesity.

In order to accomplish the above object, the present invention provides a composition for preventing and treating obesity, which comprises fermented product of a papaya husk as an active ingredient.

In one embodiment of the present invention, the fermented shell fermented product is preferably cornstarch husked, and the fermented husked fermented product is more preferably fermented by corn steeping, but is not limited thereto .

The present invention also provides a food composition for improving obesity comprising a fermented product of a Yellow Peel as an active ingredient.

Also disclosed is an animal feed additive for improving obesity and / or an animal feed composition for improving obesity, which comprises a fermented product of a perennial peel as an active ingredient.

Hereinafter, the present invention will be described.

In the present specification, the term "fermented product" refers to a product obtained by treating the roasted peel according to the conventional method of roasting the roasted peel of the fermented product, or by further processing the roasted peeled roasted peeled roasted with brown rice Means further fermentation in an incubator. The fermented product may be used as it is or may be used in liquid or powder form by reduced pressure and / or lyophilization, or may be used in the form of a liquid or a powder, or an alcohol having 1 to 4 carbon atoms such as methanol and ethanol, acetone, ethyl acetate, chloroform, methylene chloride, It can be used by extracting with a mixed solvent.

In the present specification, the above-mentioned "active ingredient" means an ingredient that exhibits the desired activity alone or can exhibit activity together with a carrier that is itself inactive.

In the present specification, "obesity" means an abnormally increased state of fat tissue, whether it is caused by genetic factors or environmental factors, and the obesity (BMI of 25 or more ) And overweight (when BMI is between 23 and 25).

In the present specification, the term "improvement, prevention and treatment of obesity" includes prevention of obesity, reduction of body fat and / or reduction of body weight, including treatment of obesity.

The composition for improving obesity of the present invention may contain the effective ingredient in an arbitrary amount (effective amount) as long as it exhibits the activity of improving obesity, the formulation, the purpose of compounding, etc. A typical effective amount is, And will be determined within the range of 0.001 wt% to 99.990 wt%. Here, "effective amount" refers to the amount of effective ingredient capable of inducing an obesity-improving effect. Such effective amounts can be determined experimentally within the ordinary skill of those skilled in the art.

The subject to which the composition of the present invention can be applied (prescription) is preferably a mammal and a person, particularly a human.

The composition for improving obesity, the composition for diet and the composition for preventing obesity complications (hereinafter referred to as "the composition of the present invention") can be grasped as a food composition in a specific embodiment.

The food composition of the present invention can be produced as a health supplement food, a special nutrition supplement food, a functional beverage and the like.

The food composition of the present invention may contain sweetening agents, flavoring agents, physiologically active ingredients, minerals and the like in addition to the active ingredients thereof.

Sweetening agents may be used in an amount that sweetens the food in a suitable manner, and may be natural or synthetic. Preferably, natural sweeteners are used. Examples of natural sweeteners include sugar sweeteners such as corn syrup solids, honey, sucrose, fructose, lactose and maltose.

Flavors may be used to enhance taste or flavor, both natural and synthetic. Preferably, a natural one is used. When using natural ones, the purpose of nutritional fortification can be performed in addition to the flavor. Examples of natural flavoring agents include those obtained from apples, lemons, citrus fruits, grapes, strawberries, peaches, and the like, or those obtained from green tea leaves, Asiatica, Daegu, Cinnamon, Chrysanthemum leaves and Jasmine. You can also use ginseng (red ginseng), bamboo shoots, aloe vera, and those obtained from banks. The natural flavoring agent may be a liquid concentrate or a powdery extract. Synthetic flavors may be used depending on the case, and synthetic flavors such as esters, alcohols, aldehydes, terpenes and the like may be used.

Examples of the physiologically active substance include catechins such as catechin, epicatechin, gallocatechin and epigallocatechin, and vitamins such as retinol, ascorbic acid, tocopherol, calciferol, thiamine and riboflavin.

As the mineral, calcium, magnesium, chromium, cobalt, copper, fluoride, germanium, iodine, iron, lithium, magnesium, manganese, molybdenum, phosphorus, potassium, selenium, silicon, sodium, sulfur, vanadium and zinc can be used.

In addition, the food composition of the present invention may contain preservatives, emulsifiers, acidifiers, thickeners and the like as needed in addition to the above sweeteners.

Such preservatives, emulsifiers and the like are preferably added in a very small amount as long as they can attain an application to which they are added. The term " trace amount " means, when expressed numerically, in the range of 0.0005% by weight to about 0.5% by weight based on the total weight of the food composition.

Examples of the preservative which can be used include calcium sodium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate and EDTA (ethylenediaminetetraacetic acid).

Examples of the emulsifier which can be used include acacia gum, carboxymethyl cellulose, xanthan gum, pectin and the like.

Examples of the acidulant that can be used include acid, malic acid, fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, and phosphoric acid. Such an acidulant may be added so that the food composition has a proper acidity for the purpose of inhibiting the growth of microorganisms other than the purpose of enhancing the taste.

Agents that may be used include suspending agents, sedimentation agents, gel formers, bulking agents and the like.

In addition, the food composition of the present invention may be any natural product known to have an activity of improving obesity, an activity of improving liver function, etc. in order to improve flavor or palatability, to enhance its functionality, or to add other functionalities Derived powder or extract.

The pharmaceutical compositions of the present invention may be formulated into oral pharmaceutical preparations (tablets, suspensions, emulsions, suspensions, etc.) including pharmaceutically acceptable carriers, excipients and the like in addition to the active ingredients. Parenteral formulations (sterile injectable aqueous or oleaginous suspensions), and localized formulations (solutions, creams, ointments, gels, lotions, patches, etc.).

The term "pharmaceutically acceptable" as used herein means that the application (subject) does not have an adaptive or higher toxicity (sufficiently low toxicity) without inhibiting the activity of the active ingredient.

Examples of pharmaceutically acceptable carriers include lactose, glucose, sucrose, starch (e.g., corn starch, potato starch and the like), cellulose, derivatives thereof (e.g. sodium carboxymethylcellulose, ethylcellulose, etc.), malt, gelatin, talc, (E.g., peanut oil, cottonseed oil, sesame oil, olive oil, etc.), polyols (e.g., propylene glycol, glycerin, etc.), alginic acid, emulsifiers (e.g., TWEENS), wetting agents (For example, sodium lauryl sulfate), a coloring agent, a flavoring agent, a tableting agent, a stabilizer, an antioxidant, a preservative, water, a saline solution and a phosphate buffer solution. The carrier may be selected from one or more of suitable pharmaceutical formulations according to the formulation of the pharmaceutical composition of the present invention.

The excipient may be selected according to the formulation of the pharmaceutical composition of the present invention. For example, when the pharmaceutical composition of the present invention is prepared by an aqueous suspension, suitable excipients include sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose , Sodium alginate, polyvinylpyrrolidone, and the like can be used. As a suitable excipient when prepared by injection, Ringer's solution, isotonic sodium chloride and the like can be used.

The composition according to the present invention is used as food or animal feed for health food, functional food, health supplement food, specific health food, beauty food and nutritional supplements (supplement) for the purpose of prevention and elimination of obesity, ). These food or animal feeds include, for example, beverages such as tea and juice; Ice cream, jelly, candy, chocolate, and chewing gum. It may also be in the form of a liquid, powder, granule, capsule or tablet. Herein, the animal for animal feed includes all animals that require prevention, elimination or treatment of obesity including animals raised in pet, animal husbandry or zoo.

The composition of the present invention may be administered orally or parenterally. The daily dose of the composition of the present invention is usually 0.001 to 1500 mg / kg body weight, and can be administered once or several times. However, since the dosage of the pharmaceutical composition of the present invention is determined in view of various related factors such as route of administration, age, sex, weight, and patient's severity of the patient, the dose is limited in any aspect to the scope of the present invention It should not be understood.

As can be seen from the present invention, the whole group in the low, middle and high concentration groups showed the effect of inhibiting weight before fermentation and after fermentation of fermented dry matter extract of the present invention, And the fermented dry extract of the present invention after the fermentation of the present invention is effective in the prevention of obesity as well as improvement of liver disease and metabolic syndrome do.

1 is a graph relating to body weight,
Figure 2 is a graph relating to dietary change,
FIG. 3 is a graph relating to the calculation of the dietary efficiency,
Figure 4 is a graph relating to organ weight changes,
Figure 5 is a graph relating to blood biochemical and cytokine testing,
Figure 6 shows histopathological examination and image observation

Hereinafter, the present invention will be described with reference to Examples and Experimental Examples. However, the scope of the present invention is not limited to these examples and experimental examples.

Example  One: Fermentation product  Manufacturing and experimental conditions

In order to enhance the pharmacological efficacy as well as to make it easy to eat by softening the medicinal product by purchasing the Dae Gwanryung 100% Dae Kwanghwoong peel which is used in the present invention and finely chopping it to the size of 1 centimeter square, 9 times, 9 times dried, (九 皇) was treated according to the traditional Jedai method.

A method for preparing a roasted poultice according to claim 1, wherein the roasted poultice is washed and dehydrated, and the roasted poultice is placed in a boil and heated at 90 to 95 ° C for 3 to 4 hours to obtain a first boiled water; A primary drying step in which the primary trough is placed in a drier and dried at 60 to 70 ° C for 20 to 24 hours to obtain a dried material; A second boiling step of putting the first-dried boiled water into a boiling machine and boiling the first boiled water at 90 to 95 ° C for 2 to 3 hours to obtain a second boiled water; The resulting second-tiered water is matured at a temperature of 90 to 95 ° C for 2 to 3 hours, and repeated seven times from the second time to a total of 9 times. And a repeated drying step of drying at each of the first to ninth tea tasting stages, wherein the drying temperature is 60 to 70 ° C and the drying time is 20 to 24 hours.

The brown rice husk produced in the Hoengseong region was changed to 20% (w / w), and fermented for 2 days in a 40 ℃ incubator.

These samples were grouped into four groups before fermentation (10% for feed) and three groups (5%, 10%, 15%) after fermentation for animal feed.

To examine liver function improvement, diet and antioxidant effect of this sample, animals were divided into 7 groups.

In the following table and below, the dried material before fermentation is named H I, and the dried material after fermentation is named H II.

Table 7 shows the experimental group.

Experimental group Delivery amount n Number The blocking method is / Lean (normal group) Non-treatment 5 When the high-fat diet method is / N.C (Negative Control, negative control) D. W 10 ml / kg 8 High-fat diet / P.C (Orlistat, positive control) 0.3% mixed (30 mg / kg) 8 High-fat diet / H Pre-fermented (H I) 10% mixed 8 High level method / H after fermentation _L (low concentration) (H II) 5% mixed 8 High level method / H after fermentation _M (medium concentration) 10% mixed 8 High level method / H after fermentation _H (high concentration) 15% mixed 8

In the table above, the normal group (C: Control) refers to an animal that has normal diet and normal environment and does not undergo any physical or surgical treatment.

Experimental Example

Preparation of test substances

The test material was mixed with high fat diets to prepare about 3 kg, aliquoted 1 kg each and refrigerated.

C57BL / 6 (Lean, DIO type) mice are widely used for anti-obesity test and mouse, C57BL / 6J, SPF (Korean BioLink, domestic) Sex, number of animals, and weight were male, 60, and 4 weeks old, respectively.

Breeding environmental conditions

The temperature is 22 ± 2 ° C, the relative humidity is 50.0 ± 15.0%, the ventilation frequency is 10-20 times / hour, the contrast time (lighting time) is 12 hours / day (07:00 ~ 19:00) 150 to 300 Lux.

In the feeding method, 2 kinds of feeds were added to the feed, and the purified water was filtered with UV sterilization and filter, and was freely ingested in a Polysulfone negative bottle (250 mL). Oral administration was performed using sonde The dose of the test solution was prepared according to the concentration, and the test substance was administered free from the day of the administration until the final administration day (day 42). In relation to the administration dose, the starting dose of the test was adjusted according to the set dose of the client , Medium, and high concentrations. The following doses were observed for 2 to 3 days of toxicity and death, and the test substance was free-fed.

Observation and inspection

General Symptom Observations: For all animals, observe general symptoms at least once daily until the day of autopsy (43 days after administration). However, after administration, the general condition should be observed and recorded by each individual.

Treatment of dead animals and dead animals: During the observation period, the dead animals and dead animals are found to be autopsied after the body weight is measured. If not possible, an autopsy should be carried out within 24 hours after refrigerated storage. In cases of painful or dying animals, symptoms are recorded and euthanized using CO ₂ gas after weighing.

Body weight measurement: For all animals, the time of group separation and the test substance are measured two to three times a week after administration.

Autopsy: After the end of the test period, all surviving animals are visually examined for major organs (lung, liver, heart, kidney, fat parts (Subcutaneous, Peritoneal, Mesentric, Epididymal) , Part of the liver and epididymal fat and subcutaneous fat (WAT) tissues are removed for biopsy and autopsied in the same way for dead animals during the experimental period.

Histopathological examination: The liver and fat (epididymal fat) tissues are removed and fixed in 10% formalin, followed by H & E and Oil red O stain. (More than 1 ~ 2 groups per group)

Biochemical and TNF-alpha measurements: The following items are examined using an automated biochemical analyzer (7020, HITACHI, JAPAN).

- Triglyceride (TG, mg / dL)

- total cholesterol (T-Chol, mg / dL)

- Glucose (GLU, mg / dL)

- Low density lipoprotein cholesterol (LDL, Cholesterol, mg / dL)

- High density lipoprotein cholesterol (HDL, Cholesterol, mg / dL)

- alanine aminotransferase (ALT (GPT), U / L)

- Aspartate aminotransferase (AST (GOT), U / L)

- blood urea nitrogen (BUN, mg / dL)

- Creatinine (Crea, mg / dL)

Use the ELISA reader to analyze the following items of the cytokine kit:

- tumor necrosis factor-alpha (TNF-alpha: pg / mL)

The ANOVA analysis was performed using Software StatView (Version 4.51, Abacus Concepts, Berkeley, Calif.) And the post-test was performed using Fisher's PLSD . Comparing the groups, the significance is verified at the significance level of 5%.

The results of the above experimental example are as follows.

Weight changes (Figure 1 and Table 2)

Five week old animals were fed low fat diet and high fat diet for 4 weeks. The control diet (Lean) was 24.0g in average weight and 29.2 (mean) g in average weight in high fat diet. The experiment was initiated with statistically significant differences. After 6 weeks of testing, the body weight of the normal control group (Lean) was increased by 2.9 g, while the weight of the negative control group (NC) was increased by 9.9 g, which was statistically significant (PC) and H II high concentration group, the difference of weight GAIN value was significantly different. It was confirmed that the weight gain was stagnated or decreased in a dose dependent manner of the H II fermentation product.

Diet amount  Change 2 and  Table 3)

The test was initiated at a statistically significant difference in the dietary intake of 3.2 g of the normal control (Lean) and 4.0 g of the daily average of the DIO negative control group. The test was carried out after the separation of the groups, and the intake was decreased in the low, medium and high concentration groups of the whole test positive group (P.C), H I and H II for 42 days. Especially, positive control group (P.C) and H II high concentration group showed more difference.

Dietary efficiency calculation  (Figs. 3 and 4)

The method of calculating the dietary efficiency is as follows. (FER = weight gain / food intake) dietary efficiency appears to be reduced in relation to the dose of the test substance, and the test substances are considered to promote energy metabolism. Dietary efficiency was significantly higher in the positive control group (P.C) and H II high concentration group and statistically significant difference was shown in the high concentration group.

Long-term weight changes (Figure 4 and Table 5)

Most organs appeared to be non-negative for the negative control compared to the normal control. However, in the whole sample-treated group, weight difference was observed in the organs including the heart compared with the negative control group, and statistical significance was significantly different between the positive control group (P.C) and the H II high concentration group. There was a significant difference in all parts of fat (subcutaneous, peritoneal, mesentric, epididymal) associated with obesity. Liver and heart tissues were also different in major organs. (PC) and H II high-concentration group, but they are expected to be tested in future experiments because they show the inhibitory effect.

Blood biochemical and Cytokine  Inspection (Figures 5 and 6)

The difference in the biochemical values of blood compared to the normal control and the negative control was confirmed, and the cholesterol level was significantly reduced or suppressed in the whole administration group compared to the negative control group. The total cholesterol level of serum lipids was statistically significant in the positive control group (P.C), HI, H II, low, medium and high concentration group compared to the negative control group. TNF-alpha was detected in the levels of cytokines and the difference of inflammatory responses of the negative control group compared to the normal group was confirmed. The results of TNF-alpha showed a tendency to decrease in the H II group as a whole but did not show significant results. Other liver enzymes, whole lipids, and cytokines are the results of the study.

Histopathological examination and image observation (Figure 6)

Figure 6 shows the oil red O and H & E stain images of the main tissues.

The induction of disease between normal control and negative control was confirmed by staining in liver and adipose tissue. Oil Red O and H & E stain method showed the difference between the control and experimental groups in lipid droplets and color in cytoplasm. It is evident that it is improved by the test product. When the animal is randomly selected, changes in the body shape before autopsy and autopsy are performed, and liver tissue and epididymal fat are excised and imaged, the size of the organ and the color of the liver tissue The difference was confirmed.

Groups Weeks Final weight gain 0 One 2 3 4 5 6 (g) L
(Lean) Mean 24.0 24.6 25.5 25.8 26.1 26.9 27.1 3.1 S.D. 1.6 1.3 1.3 1.2 1.3 1.5 1.5 0.6 NC
(Negative) Mean 29.3 30.5 33.6 35.6 37.8 39.2 40.6 11.3 * S.D. 1.4 1.5 2.0 1.5 0.9 0.9 0.9 1.2 PC
(Positive) Mean 29.2 29.7 31.6 33.2 34.3 35.1 35.6 6.5 ** S.D. 2.2 2.3 1.9 2.1 2.3 2.1 2.1 1.0 HI
(10%) Mean 29.1 29.6 32.4 34.0 36.6 38.6 39.1 10.0 S.D. 1.2 1.3 1.4 1.2 1.1 1.0 1.5 1.9 H II_L
(5%) Mean 29.4 30.1 33.1 34.3 36.1 37.6 38.7 9.3 ** S.D. 2.9 2.7 3.2 3.1 3.1 2.9 3.1 1.4 H II_M Mean 29.0 29.9 32.7 34.0 35.7 37.6 38.0 9.0 ** (10%) S.D. 1.8 1.5 2.1 2.1 2.2 2.7 2.5 1.6 H II_H
(15%) Mean 29.6 29.8 31.9 32.6 34.1 34.9 35.4 5.8 **, #, ## S.D. 2.0 1.7 1.4 1.4 1.4 2.2 2.2 1.4

Table 2 shows the body weight and the increase, with the unit being (g) and the sex being male, M: mean, SD: standard deviation, and the significant difference between L (Lean) vs NC (Negative. (p <0.05). The significant difference between NC (Negative.Control) and DIO (whole) was (t.Tests: **; P < The significant difference (t.tests: #; P <0.05) was significant (p <0.05)

Groups Weeks One 2 3 4 5 6 L
(Lean) Mean 3.3 3.2 3.1 3.4 3.4 3.3 S.D. 0.8 0.2 0.0 0.2 0.0 0.0 NC
(Negative) Mean 5.1 4.3 3.9 3.7 3.8 3.7 S.D. 0.4 1.3 0.6 0.3 0.3 0.0 PC
(Positive) Mean 3.0 3.2 3.5 3.5 2.9 2.7 S.D. 0.7 0.4 0.2 0.4 0.4 0.2 HI
(10%) Mean 5.1 3.8 4.0 3.7 3.4 3.5 S.D. 0.7 0.3 0.3 0.4 0.2 0.3 H II_L
(5%) Mean 4.6 3.4 3.8 3.7 3.4 3.3 S.D. 0.7 0.3 0.1 0.3 0.3 0.1 H II_M Mean 4.2 3.5 3.4 3.8 3.3 3.3 (10%) S.D. 0.4 1.0 0.4 0.5 0.1 0.2 H II_H
(15%) Mean 3.2 3.7 3.1 3.1 2.9 2.8 S.D. 0.2 1.0 0.2 0.4 0.2 0.2

Table 3 shows the changes in dietary allowance. The unit is (g), the sex is male, M: mean, SD: standard deviation, and the significant difference between L (Lean) vs NC (Negative. (p <0.05). The significant difference between NC (Negative.Control) and DIO (whole) was (t.Tests: **; P < The significant difference (t.tests: #; P <0.05) was significant (p <0.05)

Groups FER
No. of animals Mean ± S.D L (Lean) 5 0.9 ± 0.2 N.C (Negative) 8 3.1 ± 0.3 * P.C (Positive) 8 2.4 ± 0.4 ** H I (10%) 8 2.9 ± 0.5 H II_L (5%) 8 2.8 ± 0.4 H II_M (10%) 8 2.7 ± 0.5 H II_H (15%) 8 2.1 ± 0.5 **, #, ##

Table 4 shows the results of the FER. M: Mean, SD: Standard deviation. The significant difference (t.tests: *; P <0.05) between L (Lean) and NC (Negative.Control) (T)), NC (Negative.Control) vs DIO (whole) (t.tests: **; P <0.05) and the significant difference between HI (P <0.05). The significant difference of HII (whole) was (t.tests: ##; P <0.05)

u Weight (mg, mm) Hypertrophy Heart Kidney Liver Lung P.F M.F E.F S.F Tibia Length Cardiac (enM 169.9 385.6 1126.1 178.2 158.5 101.8 616.1 470.1 17.0 10.0 S.D. 7.8 13.4 106.8 9.4 17.0 13.3 97.3 137.4 0.2 0.4 . (eaieM 191.9 * 512.1 * 1412.6 * 202.3 * 844.2 * 389.8 * 2237.7 * 1828.5 * 17.6 * 10.9 * S.D. 17.6 49.7 64.6 28.2 44.3 57.8 396.0 159.6 0.4 0.9 . (oiieM 185.9 476.6 1262.7 ** 191.1 791.7 318.1 ** 1836.3 ** 1444.7 ** 17.1 ** 10.9 S.D. 8.2 38.6 102.0 20.0 50.2 34.2 36.4 148.0 0.4 0.4 1% M 184.7 498.9 1362.1 194.7 848.8 371.0 1988.9 1683.4 17.5 10.6 S.D. 10.6 31.2 103.6 8.5 152.6 42.4 283.3 250.7 0.2 0.6 I (% M 186.7 492.9 1288.0 ** 190.9 859.0 370.9 1900.6 1622.2 ** 17.5 10.7 S.D. 11.6 30.0 88.8 18.3 149.4 39.0 112.4 60.6 0.3 0.5 I_M 181.1 479.2 1287.8 ** 184.7 737.6 348.2 1829.3 ** 1574.8 ** 17.1 ** 10.6 1% S.D. 7.8 23.8 45.2 4.4 87.6 47.0 145.5 117.2 0.5 0.6 _5M 178.8 478.7 1222.0 ** 183.9 706.9 ** 332.0 ** 1813.6 ** 1537.3 ** 17.1 ** 10.5 S.D. 11.3 19.1 54.9 4.3 119.1 47.7 128.3 68.1 0.2 0.6

Table 5 shows the changes in long-term weights. The units are (g), sex is male, M: mean, SD: standard deviation, and L (Lean) vs NC (Negative.Control) (p <0.05). The significant difference between NC (Negative.Control) and DIO (whole) was (t.Tests: **; P < The significant difference (t.tests: #; P <0.05) was significant (p <0.05)

Groups U / L U / L mg / dL mg / dL mg / dL mg / dL mg / dL mg / dL mg / dL pg / ml GOT GPT T.C T.G HDL LDL CREA BUN GLU TNF-alpha L
(Lean) M 44.6 49.4 124.0 37.4 114.9 11.4 0.5 19.2 150.4 10.0 S.D. 3.8 7.4 15.6 6.4 10.0 0.6 0.0 1.2 8.6 1.4 NC
(Negative) M 93.8 * 89.0 * 274.2 * 56.4 * 136.5 22.0 * 0.6 * 21.0 185.2 * 12.0 S.D. 6.8 11.1 36.5 3.3 35.3 5.5 0.0 2.4 6.7 0.5 PC
(Positive) M 68.6 ** 73.8 191.6 ** 50.6 139.3 18.0 0.5 20.5 177.5 10.4 S.D. 14.6 11.8 14.8 10.2 29.5 4.4 0.1 1.8 14.5 0.7 HI
(10%) M 78.4 ** 81.0 232.2 ** 54.0 144.7 19.4 0.6 20.1 182.1 11.4 S.D. 9.3 13.4 20.5 5.3 26.6 5.1 0.0 1.1 10.1 2.6 H II_L
(5%) M 71.6 ** 80.4 205.8 ** 55.8 132.2 18.9 0.5 20.3 180.5 11.4 S.D. 6.3 8.6 13.8 9.1 15.9 1.1 0.0 2.1 13.9 1.0 H II_M M 65.6 ** 75.4 196.2 ** 56.8 149.1 19.4 0.5 20.8 177.1 11.1 (10%) S.D. 13.6 15.8 38.5 4.3 25.5 4.3 0.0 1.6 16.4 1.3 H II_H
(15%) M 61.6 ** 74.4 187.6 ** 53.6 148.6 18.6 0.5 20.0 175.7 11.2 S.D. 17.3 20.3 46.5 6.6 22.5 1.3 0.1 1.8 13.1 1.7

  Table 6 shows the biochemical changes of blood. The sexes are male, M: mean, SD: standard deviation, and the significant difference between L (Lean) vs NC (Negative.Control) <0.05). The significant difference between NC (Negative.Control) vs DIO (whole) was (t.tests: **; P <0.05) and the significant difference between HI (HI) vs HII (t.tests: #; P; 0.05). The significant difference of HII (whole)

Claims (5)

A composition for the prevention and treatment of obesity, comprising fermented product of Aspergillus oryzae as an active ingredient. The composition for preventing and treating obesity according to claim 1, wherein the fermented product of the husked peel is a corn steep husk. The composition for prevention and treatment of obesity according to any one of claims 1 to 3, wherein the fermented product is further fermented by fermenting the fermented peel. A food composition for improving obesity comprising a fermented product of a papaya peel as an active ingredient. A composition for animal feed composition for improving obesity comprising fermented peel as a active ingredient.

Images